Novartis

Arctos Medical, spun off from the University of Bern, focuses on developing innovative optogenetic therapies for treating genetic eye diseases leading to blindness. Their primary aim is to create accessible treatments for inherited retinal dystrophies (IRDs), enabling patients to potentially regain vision and improve their overall visual experience.

Cellerys, headquartered in Zurich, Switzerland, is a biotechnology company focused on developing a novel therapy for multiple sclerosis (MS). The company's core business revolves around its proprietary therapeutic platform, which aims to induce immune tolerance in MS patients. This platform employs a semi-automated, good manufacturing practice process that combines autologous red blood cells with specific peptides. By doing so, Cellerys seeks to enable healthcare providers to treat MS through antigen-specific tolerance induction, potentially improving the care and outcomes for patients with autoimmune diseases.

Arctos Medical, spun off from the University of Bern, focuses on developing innovative optogenetic therapies for treating genetic eye diseases leading to blindness. Their primary aim is to create accessible treatments for inherited retinal dystrophies (IRDs), enabling patients to potentially regain vision and improve their overall visual experience.

Anokion is a biotechnology company focused on antigen-specific immune tolerance to reduce immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. A spin-off from EPFL, it uses a platform technology that can be applied to many proteins across multiple clinical indications, including autoimmune conditions such as celiac disease, multiple sclerosis, and diabetes. The company is based in Ecublens, Switzerland.

Occlufit is a Swiss medical device company that designs and develops cardiovascular occlusion solutions. It has developed an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects. The device uses a conformable metallic mesh mounted on a compliant balloon to allow expansion and defect sealing, enabling doctors to address defects such as those in the left atrial appendage and reduce stroke risk. Founded in 2018, the company is based in Zurich, Switzerland.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Kanyos Bio is focused on creating antigen-specific immune tolerance therapies aimed at treating type 1 diabetes and celiac disease. The company was established to develop disease-modifying treatments that specifically target immune cells responsible for damaging the intestine, while preserving the function of other immune cells. This targeted approach allows for more precise treatment options, potentially leading to improved outcomes for patients. Kanyos Bio's technology has its roots at the École Polytechnique Fédérale Lausanne in Switzerland, and it collaborates with its sister company, Anokion, along with Astellas Pharma to advance its innovations in immunotherapy. Through this collaboration, Kanyos Bio seeks to leverage expertise in immunotechnology and clinical translation to bring effective therapies to market for individuals suffering from these autoimmune conditions.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Anokion is a biotechnology company focused on antigen-specific immune tolerance to reduce immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. A spin-off from EPFL, it uses a platform technology that can be applied to many proteins across multiple clinical indications, including autoimmune conditions such as celiac disease, multiple sclerosis, and diabetes. The company is based in Ecublens, Switzerland.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is a leading global medical device company specializing in ophthalmology pharmaceuticals and devices. It serves the full life cycle of eye care needs through its complementary businesses in Surgical and Vision Care.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases, areas with significant unmet medical needs.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Roche is a Swiss biopharmaceutical and diagnostics company focused on improving lives through medicines and diagnostic solutions. It develops and markets therapies across oncology, virology, inflammation, metabolism, central nervous system disorders, clinical chemistry, immunology, infectious diseases, and microbiology, and it provides in vitro diagnostics, automated instruments, software, and consumables for hospitals and research labs. The company conducts research and development and manufacturing related to molecular diagnostics, test systems, and test kits, including PCR-based assays through its molecular diagnostics initiatives. Its portfolio includes cancer treatments such as Avastin, Herceptin, and MabThera, and the organization serves hospitals, laboratories, physicians, and patients worldwide with integrated drug and diagnostic offerings. Roche operates globally, combining drug development with diagnostic services to support disease detection, monitoring, and personalized medicine.

Spexis AG is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs and antibiotics to address severe or life-threatening diseases. Founded in 1996, the company focuses on addressing high unmet medical needs, particularly in the areas of antibiotic resistance and respiratory diseases. Spexis's lead product, murepavadin, is currently in Phase III development targeting Pseudomonas aeruginosa, a pathogen identified as a critical priority by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of innovative therapeutics in the respiratory domain.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.